TherapeuticsMD, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
TXMD$1.69-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share amounts)
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue, net: | ||
| License and service revenue | $1,761 | $1,302 |
| Operating expenses: | ||
| Selling, general and administrative | 4,744 | 8,903 |
| Impairment of long-lived assets (Note 4) | 1,268 | — |
| Depreciation & amortization | 509 | 922 |
| Total operating expenses | 6,521 | 9,825 |
| Loss from operations | (4,760) | (8,523) |
| Other income (expense): | ||
| Miscellaneous income | 2,417 | 781 |
| Total other income | 2,417 | 781 |
| Loss from continuing operations before income taxes | (2,343) | (7,742) |
| Benefit for income taxes | 31 | 43 |
| Net loss from continuing operations | (2,312) | (7,699) |
| Income (loss) from discontinued operations, net of income taxes | 131 | (2,579) |
| Net loss | $(2,181) | $(10,278) |
| Loss per common share, basic: | ||
| Continuing operations | (0.20) | (0.74) |
| Discontinued operations, net | 0.01 | (0.25) |
| Net loss per common share, basic | $(0.19) | $(0.99) |
| Loss per common share, diluted: | ||
| Continuing operations | (0.20) | (0.74) |
| Discontinued operations, net | 0.01 | (0.25) |
| Net loss per common share, diluted | $(0.19) | $(0.99) |
| Weighted average common shares, basic | 11,532 | 10,441 |
| Weighted average common shares, diluted | 11,532 | 10,441 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.